No association between use of angiotensin‐converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID‐19 in the COvid MEdicaTion (COMET) study

Since the outbreak of SARS‐CoV‐2, also known as COVID‐19, conflicting theories have circulated on the influence of angiotensin‐converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) on incidence and clinical course of COVID‐19, but data are scarce. The COvid MEdicaTion (COMET...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Br J Clin Pharmacol
Egile Nagusiak: Sablerolles, Roos S. G., Hogenhuis, Freija E. F., Lafeber, Melvin, van de Loo, Bob P. A., Borgsteede, Sander D., Boersma, Eric, Versmissen, Jorie, van der Kuy, Hugo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2021
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8014637/
https://ncbi.nlm.nih.gov/pubmed/33507556
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14751
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak